Merus

Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.

Proprietary Multiclonics® platform for creating full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies with manufacturing and pharmacokinetic profiles similar to conventional monoclonal antibodies, also enabling the creation of antibody-drug conjugates (ADClonics®).